Jinyu Medical announced that the company previously reviewed and approved a subscription for the newly issued shares of Hong Kong DRA COMPANY LIMITED, with a total investment of 150 million yuan equivalent to HKD over three phases. After evaluating the high-end non-invasive prenatal testing market based on the market environment and actual business development, the company and DRA's founding shareholders decided to liquidate and terminate operations. The company received a cancellation notice from the Hong Kong Registry on October 12, 2026, and DRA was announced to be withdrawn and dissolved on October 9, 2026. The termination of foreign investment will not have a significant adverse impact on the company's production, operation and financial situation.

According to Jinyu Medical's announcement, the company previously reviewed and approved a subscription for newly issued shares of Hong Kong DRA COMPANY LIMITED, with a total investment of 150 million yuan equivalent to HKD over three phases. After evaluating the high-end non-invasive prenatal testing market based on the market environment and actual business development, the company and DRA's founding shareholders decided to liquidate and terminate operations. The company received a cancellation notice from the Hong Kong Registry on October 12, 2026, and DRA was announced to be withdrawn and dissolved on October 9, 2026. The termination of foreign investment will not have a significant adverse impact on the company's production, operation and financial situation.